Rotigotine
Rotigotine structure
|
Common Name | Rotigotine | ||
|---|---|---|---|---|
| CAS Number | 99755-59-6 | Molecular Weight | 315.473 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 470.1±45.0 °C at 760 mmHg | |
| Molecular Formula | C19H25NOS | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 238.1±28.7 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
Food Chem. Toxicol. 52 , 143-52, (2013) Continuous dopaminergic stimulation (CDS) is an important drug development strategy in the treatment of Parkinson's disease (PD). Rotigotine is a non-ergoline D(3)/D(2)/D(1) dopamine receptor agonist for treating PD. As a new treatment option for CDS, rotigot... |
|
|
Medication update.
Nurse Pract. 37(6) , 56, (2012)
|
|
|
ADMET considerations for restless leg syndrome drug treatments.
Expert Opin. Drug Metab. Toxicol. 8(10) , 1247-61, (2012) Restless legs syndrome (RLS) is a common neurological disorder that might impair nocturnal rest causing decreased alertness, depressed mood, reduced job performance, and poor quality of life. In patients affected by severe RLS, a pharmacological treatment is ... |
|
|
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
J. Neurol. Neurosurg. Psychiatr. 85(8) , 840-4, (2014) Impulse control disorders (ICDs) encompass a wide spectrum of abnormal behaviour frequently found in cases of Parkinson's disease (PD) treated with dopamine agonists (DAs). The main aim of this study was to analyse ICD prevalence with different DAs.We carried... |
|
|
Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease).
Sleep Med. 13(2) , 151-5, (2012) It is often assumed that most patients with restless legs syndrome (RLS) only experience symptoms at night. However, previous studies have estimated the prevalence of daytime symptoms to be 10-60%. This study sought to investigate the prevalence and pattern o... |
|
|
Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline.
Expert Opin. Pharmacother. 12(13) , 1985-98, (2011) The aim of this research is to characterize further the potential motor and non-motor benefits of rotigotine reported in the double-blind, placebo-controlled RECOVER trial primary publication, by performing a post hoc exploratory analysis of patient status (s... |
|
|
The powerful pre-treatment effect: placebo responses in restless legs syndrome trials.
Eur. J. Neurol. 19(10) , 1305-10, (2012) To investigate whether dopaminergic pre-treatment alters placebo and dopamine agonist responses in restless legs syndrome (RLS).Two large, multi-centre trials (SP790 and SP792; registration numbers NCT00136045 and NCT00135993) on the efficacy of rotigotine in... |
|
|
Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome.
Prog. Neuropsychopharmacol. Biol. Psychiatry 40 , 326-33, (2013) The present study aimed to examine the long-term efficacy and safety of rotigotine treatment for restless legs syndrome (RLS), as well as the rate of clinically significant augmentation, in a 1-year open-label study of Japanese subjects. Japanese patients wit... |
|
|
Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Fundam. Clin. Pharmacol. 27(1) , 81-95, (2013) Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or ... |
|
|
Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Curr. Med. Res. Opin. 27(10) , 1899-905, (2011) The dopamine agonist rotigotine has shown efficacy and safety for the treatment of early and advanced Parkinson's disease (PD) in controlled clinical trials. This observational study evaluated rotigotine administration in combination with other antiparkinsoni... |